Top news of the week: 03.10.2022.
Intercept's OCA fails a PhIII NASH trial, raising fresh doubts about its yearslong quest for an OK
Intercept Pharmaceuticals has run into another big setback in its yearslong quest to win an approval for OCA in NASH. The biotech put out word Friday morning that its Phase III REVERSE ...
Oncology Co.'s Shares Erupt on Signing Global License Deal Trending Company
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with ...
AiCuris´ innovation accelerator AiCubator calls for innovative proposals to propel anti-infective drug development in the third round
The AiCubator program was launched to provide first-hand support to fuel early research projects of young start-ups and academic teams that have the potential to become the next …
Interim Results From Phase 2b Trial Are 'Encouraging' Research Report
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.
‘Longtermism’ Movement Misses the Importance of War
A moral movement called longtermism, which focuses on protecting humanity’s future, dwells too much on artificial intelligence and not enough on war
Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts
St Andrews, UK – 28 September 2022 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment …
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current...